905 filings
Page 2 of 46
6-K
bnrkexj0 lhjt
1 Feb 23
Novartis continues to grow with further core margin expansion and achieves important innovation milestones
7:53am
6-K
xizb0ul7ebzyuyd
5 Dec 22
Current report (foreign)
9:27am
6-K
6xt080rx2qi1nf
25 Oct 22
Current report (foreign)
9:40am
6-K
0guue5vvjaffz1mrls
24 Oct 22
Current report (foreign)
6:05am
6-K
qw4mfq2s81rx9yrqdh
21 Sep 22
Current report (foreign)
6:05am
6-K
1ohc6 wejxo5hjann
25 Aug 22
Current report (foreign)
8:58am
6-K
ovb9zaizr dox13mct4
19 Jul 22
Novartis delivers continued strong momentum of key growth brands, progress on strategic initiatives and confirms FY’22 Group guidance
6:49am
6-K
mjdfvu5t824et
21 Jun 22
Current report (foreign)
4:21pm
6-K
4qhf60e9sjj93s ad3wp
26 Apr 22
Novartis delivers solid sales and profit growth. Strong performance of in-market brands supports confidence in mid-term growth outlook
9:04am
6-K
ebo4vu48fr1yn3ham
4 Apr 22
Current report (foreign)
6:08am
6-K
jfrch tfxb
23 Mar 22
Current report (foreign)
7:48pm
6-K
udxu3fwt03o qxhf
2 Feb 22
Financial Results | Résultats Financiers | Finanzergebnisse
7:28am
6-K
skrx4a0ul
22 Dec 21
Current report (foreign)
4:41pm
6-K
i021af2vrie9v2s0
20 Dec 21
Current report (foreign)
6:05am
6-K
r3t5 tp75
17 Dec 21
Current report (foreign)
8:07am
6-K
uuedom
4 Nov 21
Current report (foreign)
6:43am
6-K
dxno auyymx7
26 Oct 21
Novartis delivers solid Q3 results, with strong growth in Innovative Medicines. Announces strategic review of Sandoz
9:39am
6-K
oxpou5wz1rw0jnjw4bx0
25 Oct 21
Current report (foreign)
6:05am
6-K
weg2j
3 Aug 21
Current report (foreign)
6:30am
6-K
f57rqzlwkvqv j1t
21 Jul 21
Financial Results | Résultats Financiers | Finanzergebnisse
6:55am